Purpose: Long non-coding RNAs (lncRNAs) play critical regulatory roles in the tumorigenesis of GC. This study aimed to investigate the regulatory effect and mechanism of lncRNA-HCG18 on GC. Methods: The expression of lncRNA-HCG18 was detected in GC tissues and cell lines by qRT-PCR. LncRNA-HCG18 was silenced in AGS and MGC803 cells by the transfection of lncRNA-HCG18 siRNA (si-HCG18). MTT, transwell and Annexin V-PI double staining assay were performed to assess the proliferation, migration, invasion and apoptosis of GC cells. The expression of PI3K/Akt pathway-, apoptosis-, and migration-related proteins were detected by Western blot. An activator of PI3K/Akt pathway 740 Y-P was used to activate the PI3K/Akt pathway in AGS cells. A human tumor xenograft model was established in mice to evaluate the effects of si-HCG18 in vivo. Results: LncRNA-HCG18 was overexpressed in GC tissues and cells. Up-regulation of lncRNA-HCG18 was positively correlated with the stage of tumor node metastasis and invasion depth. Silencing of lncRNA-HCG18 suppressed the proliferation, migration and invasion, and induced the apoptosis of GC cells. Silencing of lncRNA-HCG18 blocked the PI3K/Akt pathway. The intervention of 740Y-P reversed the anti-tumor effect of lncRNA-HCG18 on GC cells. In addition, silencing of lncRNA-HCG18 suppressed the growth of GC xenografts in mice. Conclusion: Silencing of lncRNA-HCG18 inhibited the tumorigenesis of GC through blocking the PI3K/Akt pathway, suggesting a novel therapeutic target for GC.
Introduction
Gastric cancer (GC) is a common type of malignancy, which is the second leading cause of cancer-related death worldwide. 1, 2 The high metastatic potential of GC leads to the poor prognosis of patients, with a 5-year survival rate of less than 20%. 3 Although the surgery and adjuvant chemotherapy have made great progress in the treatment of GC, the prognosis of GC patients is still poor since more than 80% of patients are diagnosed in the advanced stage. [4] [5] [6] Therefore, identifying novel targets for the diagnosis and treatment of GC are urgently needed.
Long non-coding RNAs (lncRNAs) are linear RNA transcripts of the mammalian genome without protein-coding function. 7 Recently, various cancer-related lncRNAs have been identified, and their biological functions in tumorigenesis have also been confirmed, such as lncRNA-MALAT1 in prostate cancer, 8 and lncRNA-HOTAIR 9 and lncRNA-ANRIL 10 in cervical cancer. It is worth mentioning that lncRNAs exert critical regulatory roles in the development of GC. Zhao et al 11 have shown that overexpression of lncRNA-HULC promotes the proliferation and invasion, and inhibits the apoptosis of SGC7901 cells. Li et al 12 have indicated that overexpression of lncRNA-CASC2 inhibits the growth of GC cells via blocking the MAPK pathway. Wu et al have proved that silencing of lncRNA-FEZF1-AS1 represses the tumorigenesis of GC by activating the Wnt/βcatenin pathway. 13 LncRNA-human leucocyte antigen complex group 18 (HCG18) is a 2430-bp lncRNA located on chromosome 6p22.1. Xi et al 14 have found that lncRNA-HCG18 represses the growth of nucleus pulposus (NP) cells and accelerates the development of intervertebral disc degeneration (IDD). Si-Yu et al 15 have determined a tumorpromoting role of lncRNA-HCG18 on liver cancer. However, the biological function of lncRNA-HCG18 on GC remains unclear.
Phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway is indispensable in the progression of cancers, which can modulate the tumorigenesis, metastasis, and cell proliferation and apoptosis. 16 Recently, accumulating researches have suggested that the regulatory effects of lncRNAs on GC are closely related to the PI3K/Akt pathway. 17 For examples, lncRNA AK023391 accelerates the proliferation and invasion of GC cells via activating the PI3K/Akt pathway. 18 LncRNA-UCA1 accelerates the tumorigenesis of GC via modulating the proteins and downstream mediators involving the PI3K/Akt pathway. 19 LncRNA CRNDE plays an important role in promoting GC progression by activating the PI3K/Akt pathway. 20 Thus, we attempted to determine whether the regulatory role of lncRNA-HCG18 on GC is associated with the PI3K/Akt pathway.
In this study, we investigated the regulatory effect of lncRNA-HCG18 on GC and the underlying mechanism involving the PI3K/Akt pathway. The expression of lncRNA-HCG18 was detected in GC tissues and cell lines. Functional experiments were performed to determine the role of lncRNA-HCG18 on the tumorigenesis of GC in vitro and in vivo. Our findings may reveal a novel therapeutic target for GC, and provide a new insight into the underlying mechanism for the treatment of GC.
Materials and Methods

Tissue Samples
Forty-five patients with GC (29 males and 16 females; average age 59.12 ± 6.79 years) were screened from April 2017 to May 2018 in our hospital. Paired tumor tissues and adjacent normal tissues (ANT) were obtained from patients underwent surgical resection. Patients had not received preoperative adjuvant chemotherapy, radiotherapy, targeted therapy or immunotherapy before surgical resection. Pathological diagnosis was performed in accordance with the WHO classification criteria of digestive system tumors (2010 edition). This study was approved by the Local ethics committee, and informed consents were obtained from all patients.
Cell Culture
Normal human gastric epithelial cell line (GES-1) and GC cell lines (MKN45, MGC803, AGS) were obtained from Shanghai Cell Bank of the Chinese Academy of Sciences (Shanghai, China). All cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Hyclone, logan, Utah, USA) containing 10% fetal bovine serum (FBS; Hyclone) and cultured in an incubator (MCO-15AC, SANYO, Japan) at 37°C. When reaching 90% confluence, cells were passaged at a ratio of 1:3. Logarithmic growth phase cells were used for subsequent experiments.
Cell Transfection
LncRNA-HCG18 siRNAs (si-HGC18-1 and si-HGC18-2) and siRNA negative control (si-NC) were purchased from Sangon Biotech Co., Ltd (Shanghai, China). AGS and MGC803 cells were transfected with si-HCG18 or si-NC using Lipofectamine 2000 reagent (Invitrogen, Waltham, MA, USA). Cells without transfection were considered as the Blank control. In addition, the transfected AGS cells were further treated with an activator of PI3K/Akt pathway 740 Y-P (50 μg/mL, TocrisBioscience, Ellisville, MO, USA).
qRT-PCR
Total RNA was extracted from GC tissues and cells using TRIzol TM Plus RNA Isolation Reagents (Invitrogen, Waltham, MA, USA). A Reverse Transcription Kit (Takara, Otsu, Japan) was used for reverse transcription. qRT-PCR was performed on an ABI 7500HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) under the following conditions: 95°C for 10 min, 40 cycles at 95°C for 10 s, 60°C for 20 s and 72°C for 34 s. GAPDH was used as the internal control. The mRNA expression level was calculated using the 2 −ΔΔCt method. The primer sequences were HCG18, forward: 5′-ATCCT GCCAATAGATGCTGCTCAC-3, reverse: 5′-AGCCAC CTTGGTCTCCAGTCTC-3′; GAPDH, forward: 5′-TG ACGTGCCGCCTGGAGAAAC-3, reverse: 5′-CCGGCA TCGAAGGTGGAAGAG-3′.
Western Blot
Total proteins were isolated from cells using RIPA Lysis Buffer (Elabscience, Wuhan, China), and then quantified using a BCA Protein Assay Kit (ThermoFisher, SanJose, CA, USA). The protein samples were separated by 10% SDS-PAGE and transferred onto a polyvinylidene fluoride (PVDF) membrane. The membrane was then blocked in 5.0% non-fat milk for 45 min and incubated with primary antibody at 4°C overnight. The primary antibodies included anti-GAPDH (1:1000, ab9485, Abcam, Cambridge, England), -PI3K (1:1000, 4292, CST, Danvers, MA, USA), -p-PI3K (1:1000, 17,366, CST), -Akt (1:1000, 9272, CST), -p-Akt (1:1000, 4060, CST), -MMP-2 (1:1000, ab97779, Abcam), -MMP-9 (1:1000, ab38898, Abcam,), -Bcl-2 (1:1000, ab32124, Abcam), and -Bax (1:1000, ab32503, Abcam). Subsequently, the membrane was incubated with HRP-conjugated goat anti-rabbit IgG (1:10,000, G-21234, Invitrogen) for 1 h at 25°C. Protein bands were visualized using a Chemiluminescent Substrate Kit (Bio-Rad, Hercules, CA, USA). GAPDH was used as the internal control.
MTT Assay
Cells were seeded into 96-well plates (6 × 10 3 cells/well, 200 μL/well) and cultured in an incubator at 37°C for 0, 24, 48, and 72 h, respectively. MTT (5 mg/mL, 20 μL/well, Sigma, San Antonio, TX, USA) was then added into each well. After 4 h of incubation, DMSO (150 μL/well) was added to terminate the reaction. The optical density at 495 nm (OD 495 ) was measured by a Microplate Reader (Applied Biosystems).
Annexin V-Propidium Iodide (PI) Double Staining
Cell apoptosis was detected using an Annexin V-fluorescein isothiocyanate (FITC)/PI Kit (Invitrogen). Briefly, cells were seeded into 6-well plates (1 × 10 5 cells/well, 500 µL/well) and then stained with 5 µL Annexin V-FITC and 5 mL PI for 10 min at 25°C in the dark. The cell apoptosis was assessed by a MUSE TM flow cytometer (MerckMillipore, Billerica, MA, USA).
Wound Healing Assay
Cells were seeded into 6-well plates (1 × 10 6 cells/well), and cultured until 90% confluence. A scratch was then made using a sterile pipette tip. After 48 h of culturing, the wound area was photographed and measured under an optical microscope (Olympus Ckx53, Tokyo, Japan) using Image J Software.
Transwell Invasion Assay
Cell invasion was detected using a Transwell Chamber (BD Biosciences, Franklin Lakes, NJ, USA). Briefly, cells were seeded in the upper chamber pre-coated with matrigel. The medium containing 10% FBS was added to the lower chamber. After 48 h of culturing, cells on the upper chamber were removed. Cells in the lower chamber were stained with 0.1% crystal violet for 30 min, and counted under a microscope (Olympus Ckx53) at five randomly selected fields.
Establishment of Xenograft Tumor Model in Mice
Twelve Male nude mice (BALB/c, 4 weeks old) were obtained from Shanghai experimental animal center, Chinese academy of sciences (Shanghai, China). Mice were randomly divided into three groups: Mock, si-NC and si-HCG18 group (n = 4 each group). AGS cells were subcutaneously injected into the left axilla (1 × 10 7 cells/ mice, 0.2mL/mice). The longest diameter (L) and the shortest diameter (W) of the tumor xenograft were measured with a vernier caliper every 7 days after injection. The tumor volume was calculated using the following formula: V = L ×W 2 /2. At the end of the 4th-week postinjection, mice were anesthetized with pentobarbital sodium (60 mg/kg), and killed by cervical dislocation. The tumor xenografts were dissected completely and then weighed. Animal experiments were performed in accordance with the "Guidelines for the Care and Use of Laboratory Animals" published by the National Institutes of Health and were approved by Linyi Cancer Hospital's ethics committee.
Statistical Analysis
All experiments were performed in triplicates and repeated at least three times. Data were presented as means ± standard deviation (SD) and analyzed by SPSS 22.0 statistical software (SPSS Inc., Chicago, IL). Student's t-test was used to analyze the differences between the two groups. One-way ANOVA followed by Tukey's post hoc test was used to analyze the differences among multigroups. Differences were considered statistically significant at P < 0.05.
Results
LncRNA-HCG18 Was Overexpressed in GC Tissues
The expression of lncRNA-HCG18 in tumor tissues (GC) and adjacent normal tissues (ANT) were detected by qRT-PCR. As shown in Figure 1A , the expression of lncRNA-HCG18 was significantly higher in the GC group than that in the ANT group (P < 0.0001). In addition, the expression of lncRNA-HCG18 was significantly higher in tumors at I/ II stage than that in tumors at III/IV stage (P < 0.0001), and was significantly higher in tumors at T1-2 stage than that in tumors at T3-4 stage (P < 0.0001, Figure 1B and C). The above results indicated that lncRNA-HCG18 was overexpressed in GC tissues, and overexpression of lncRNA-HCG18 was positively correlated with the stage of tumor node metastasis and invasion depth.
Silencing of lncRNA-HCG18 Repressed the Proliferation and Induced the Apoptosis of GC Cells
The expression of lncRNA-HCG18 was detected in three GC cell lines (MKN45, MGC803, AGS) and normal human gastric epithelial cells (GES-1). qRT-PCR showed that the expression of lncRNA-HCG18 expression in GC cell lines (MKN45, MGC803, AGS) was significantly higher than that in GES-1 cells (P < 0.001, Figure 2A ). MGC803 and AGS cells with relatively high lncRNA-HCG18 expression were used for the following experiments. LncRNA-HCG18 was then silenced in MGC803 and AGS cells by the transfection of si-HCG18-1/2. qRT-PCR showed that the expression of lncRNA-HCG18 in the si-HCG18-1/2 group was significantly lower than that in the Blank group (P < 0.01, Figure 2B ). si-HCG18-1 with relatively high silence efficiency was used for the subsequent experiments. MTT assay showed that the OD 495 values at 48 and 72 h post-culturing were significantly decreased in the si-HCG18 group compared with Blank group (P < 0.05, Figure 2C) . In contrast to cell proliferation, si-HCG18 promoted the apoptosis of MGC803 and AGS cells (P < 0.01, Figure 2D ).
Silencing of lncRNA-HCG18 Inhibited the Migration and Invasion of GC Cells
Wound healing and transwell assay were performed to detect the migration and invasion of MGC803 and AGS cells, respectively. Both the migration and invasion ability of cells in si-HCG18 group were significantly decreased compared with those in the Blank group (P < 0.01, Figure 3A and B).
Silencing of lncRNA-HCG18 Blocked the PI3K/Akt Pathway
In order to explore the regulatory mechanism of lncRNA-HCG18 involving the PI3K/Akt pathway, the expression of PI3K/Akt pathway-related proteins was detected by Western blot. The protein expression levels of p-AKT/ AKT and p-PI3K/PI3K in MGC803 and AGS cells were significantly decreased in the si-HCG18 group compared with the Blank group (P < 0.01, Figure 4 ).
Activation of the PI3K/Akt Pathway Reversed the Anti-Tumor Effect of LncRNA-HCG18 Silencing on GC Cells
In order to investigate whether the effects of lncRNA-HCG18 on GC cells were associated with the PI3K/Akt pathway, an activator of PI3K/Akt pathway, 740 Y-P was used to activate the PI3K/Akt pathway in AGS cells. As shown in Figure 5A , 740 Y-P reversed the inhibiting effect of si-HCG18 on the PI3K/Akt pathway (P < 0.05). In 
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OncoTargets and Therapy 2020:13 addition, 740 Y-P reversed the inhibiting effects of si-HCG18 on the proliferation, migration, invasion of AGS cells, and reversed the promoting effect of si-HCG18 on the apoptosis of AGS cells (P < 0.05, Figure 5B -E). The expression of apoptosis-and migration-related proteins was further detected by Western blot. As shown in Figure 5F , the protein expression of MMP-2, MMP-9 and Bcl-2 was significantly decreased, and the protein expression of Bax was significantly increased in si-HCG18 group compared with those in si-NC group (P < 0.01). The intervention of 740 Y-P significantly reversed the expression of the above proteins in AGS cells (P < 0.05, Figure 5F ).
Silencing of lncRNA-HCG18 Inhibited the Growth of GC Xenografts in Mice
A human tumor xenograft model in mice was established to evaluate the anti-tumor effect of lncRNA-HCG18 silencing on GC in vivo. As shown in Figure 6A -C, the tumor volume and weight were significantly decreased in the si-HCG18 group compared with the Mock group (P < 0.01). These results demonstrated that the silencing of lncRNA-HCG18 repressed the growth of GC xenografts in mice.
Discussion
The development of GC is a complicated biological process involving multiple factors and signaling pathways.
Previous studies have proved that lncRNAs are dysregulated in GC, such as the up-regulation of lncRNA-HOAIR and -ANRIL, and the down-regulation of lncRNA-MEG3 and -GAS5. [21] [22] [23] [24] Huang et al 25 have shown that the expression of lncRNA-LINC00673 is up-regulated in GC and positively related to the poor prognosis of GC patients. Du et al 26 have found that the expression of lncRNA-CRNDE is increased in GC tissues and cell lines, and is positively associated with the depth of invasion, TNM stage and lymph node metastasis. Sun et al 23 have revealed that lncRNA-GAS5 acts as a tumor-inhibitor in GC and a negative prognostic factor in GC patients. However, the specific role of lncRNA-HCG18 in GC remains unclear. In this study, the expression of lncRNA-HCG18 was significantly up-regulated in GC tumor tissues and was positively associated with the stage of tumor node metastasis and invasion depth. Similar with the previous researches, our findings indicate that lncRNA-HCG18 is a tumor promoter in GC.
LncRNA-HCG18 plays a promoting role in the development of IDD, which is involved in the proliferation and apoptosis of NP cells. 14 However, researches on the regulatory effects of lncRNA-HCG18 on GC cells are limited. Xu et al 27 have demonstrated that NOTCH1 represses the progression of bladder cancer via cooperating with lncRNA-HCG18. Si-Yu et al 15 have found that the upregulation of lncRNA-HCG18 promotes the proliferation and invasion, inhibits the apoptosis of hepatocarcinoma (HCC) cells. Qu et al 28 have illustrated that lncRNA-HCG18 promotes the proliferation and migration of nonsmall cell lung cancer (NSCLC) cells. Consistent with the function of lncRNA-HCG18 in HCC and NSCLC, 为 lncRNA-HCG18 promoted the proliferation, migration, invasion, and inhibited apoptosis of GC cells. Our results indicate that lncRNA-HCG18 is an oncogenic factor in GC. Furthermore, a tumor xenograft model in mice was established to evaluate the role of lncRNA-HCG18 on GC in vivo. In consistent with in vitro results, we found that silencing of lncRNA-HCG18 inhibited the growth of GC xenografts in mice. PI3K/Akt pathway exerts critical effects in modulating the biological processes of cell growth, survival, proliferation, invasion and apoptosis. 29 PI3K/Akt pathway is involved in many types of human cancers including GC. [30] [31] [32] The aberrant activation of the PI3K/Akt pathway is closely related to the progression of GC. 16 Li et al 33 have shown that LEMD1 promotes the proliferation of GC cells through activating the PI3K/Akt pathway. Huang et al 18 have revealed that lncRNA-AK023391 promotes the tumorigenesis of GC through activating the PI3K/Akt pathway. Du et al 20 have proved that lncRNA-CRNDE promotes the proliferation, migration and invasion of GC cells through activating the PI3K/Akt pathway. 25 In this study, we found that silencing of si-HCG18 blocked the PI3K/Akt pathway in GC cells. In order to further identify whether the effects of lncRNA-HCG18 on GC cells were associated with the PI3K/Akt pathway, 740 Y-P (an activator of PI3K/Akt pathway) was used to treat GC cells. The results showed that 740 Y-P significantly reversed the anti-tumor effect of si-HCG18 on AGS cells. We speculate that silencing of lncRNA-HCG18 may promote the proliferation, migration and invasion, and inhibit the apoptosis of GC cells by blocking the PI3K/Akt pathway. 
Conclusions
In summary, lncRNA-HCG18 was up-regulated in GC tissues and cell lines. Silencing of lncRNA-HCG18 promoted the proliferation, migration and invasion, and inhibited the apoptosis of GC cells by blocking the PI3K/Akt pathway. Silencing of lncRNA-HCG18 could also inhibit the growth of GC xenografts in mice. LncRNA-HCG18 is an oncogene in GC, which may be used as a novel therapeutic target in clinical practice.
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